Deakin University
Browse

File(s) under permanent embargo

The effect of combined treatment with SSRIs and renin-angiotensin system (RAS) drugs: A propensity score matched cohort study

journal contribution
posted on 2020-03-01, 00:00 authored by O Köhler-Forsberg, L Petersen, Michael BerkMichael Berk, C Gasse, S D Østergaard
Drugs acting on the renin-angiotensin system (RAS) may have beneficial effects on mental health. We investigated whether use of drugs acting on the RAS, as add-on to selective serotonin reuptake inhibitors (SSRIs), was associated with a reduced risk of psychiatric hospital contacts. We identified all individuals initiating treatment with an SSRI between 1997 and 2012. Individuals using an SSRI without concomitant use of a RAS drug (SSRI-only users) were propensity score matched 1:1 to individuals using both an SSRI and a drug acting on the RAS (SSRI+RAS users). The SSRI-only and SSRI+RAS users were followed for up to three years or until December 31, 2013. We performed Cox proportional hazard regression analyses to calculate risks for psychiatric hospital contacts, hospital contacts due to depression, suicidal behavior, and all-cause mortality. We followed 30,311 SSRI-only users and 30,311 SSRI+RAS users for a total of 49,327 person-years. Compared to SSRI-only users, concomitant use of SSRI+RAS was associated with a significantly reduced risk for psychiatric hospital contacts (hazard rate ratio (HRR)=0.91; 95%-confidence intervals (95%-CI)=0.84–0.98) and lower mortality rate (HRR=0.70; 95%-CI=0.66–0.75). The associations between SSRI+RAS use and psychiatric hospital contacts for depression (HRR=0.92; 95%-CI=0.80–1.05) and suicidal behavior (HRR=1.06; 95%-CI=0.79–1.42) were not statistically significant. In this observational cohort study, concomitant use of an SSRI and a drug acting on the RAS was associated with a slightly reduced risk for psychiatric hospital contacts, when compared to use of an SSRI alone.

History

Journal

European Neuropsychopharmacology

Volume

32

Pagination

120 - 130

Publisher

Elsevier

Location

Amsterdam, The Netherlands

ISSN

0924-977X

eISSN

1873-7862

Language

eng

Publication classification

C1 Refereed article in a scholarly journal

Copyright notice

2020, Elsevier B.V. and ECNP